Convatec is a multinational medical products and technologies company based in the United Kingdom. The company specializes in the development and manufacturing of products for advanced wound care, ostomy care, continence and critical care, and infusion devices. Convatec was originally founded in 1978 as a division of E.

R. Squibb & Sons, an American pharmaceutical company. It became an independent company in 1998 when Bristol-Myers Squibb spun off its medical devices division, including Convatec, as a separate entity.

In 2008, Convatec was acquired by private equity firms Nordic Capital and Avista Capital Partners. The company's headquarters are located in Reading, Berkshire, in the United Kingdom. It also has a significant presence in the United States, with operations in Greensboro, North Carolina, and Skillman, New Jersey.

Additionally, Convatec has manufacturing facilities in several countries, including the United Kingdom, the United States, Mexico, the Dominican Republic, and China. Convatec offers a wide range of products and solutions for healthcare professionals and patients. These include advanced wound dressings, negative pressure wound therapy systems, ostomy bags and accessories, continence care products, and infusion devices.

The company aims to improve patient outcomes and quality of life by providing innovative and efficient solutions for managing complex and chronic conditions. On a global scale, Convatec has a strong market presence. Its products are sold in over 125 countries worldwide, and the company has established partnerships with various healthcare institutions and distributors.

Convatec has also made significant acquisitions to expand its product portfolio and customer base. In 2017, the company acquired Woodbury Holdings, a leading provider of wound dressing solutions, further strengthening its position in the advanced wound care market. In terms of market position, Convatec is considered to be a major player in the medical products industry, competing with other multinational companies such as Coloplast, Hollister, and 3M.

The company has a dedicated sales force that works closely with healthcare professionals to provide specialized support and develop customized solutions. In recent years, Convatec has undergone strategic changes to drive growth and innovation. The company has focused on developing new products and technologies, as well as expanding into emerging markets.

Convatec has also invested in research and development to continuously improve its existing product lines and address the evolving needs of patients and healthcare providers. As of the latest available information, Convatec continues to operate as a leading global medical products company, committed to delivering innovative solutions for the management of acute and chronic conditions